Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel

Background: HER2-positive advanced breast cancer (ABC) is associated with significant heterogeneity in long-term disease control and survival. Prognostic models for HER2-positive ABC patients considering first-line pertuzumab, trastuzumab, and docetaxel have not been evaluated. Methods: A pre-treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Hopkins, Ashley M., Rowland, Andrew, McKinnon, Ross A., Sorich, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713878/
https://www.ncbi.nlm.nih.gov/pubmed/31508358
http://dx.doi.org/10.3389/fonc.2019.00789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713878/
https://www.ncbi.nlm.nih.gov/pubmed/31508358
http://dx.doi.org/10.3389/fonc.2019.00789

Ejemplares similares